Named on 2 rounds in the feed, most often at Series B and in Biotech.
Rounds from ~ 2025-04 to 2025-05-13
ROUNDS
2
led every one
LED ROUNDS · USD
$150.8M
across 2 rounds · 2 co-led, split evenly
CO-INVESTORS
10
named beside it
Named on 2 rounds in the feed, most often at Series B and in Biotech.
Rounds from ~ 2025-04 to 2025-05-13
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Azafaros Azafaros develops therapeutics for patients with rare metabolic disorders, particularly those affecting the lysosomal storage system. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $146.7M | 2025-05-13 | [ LEAD ] |
Airna AIRNA develops RNA editing therapeutics aimed at delivering functional cures for patients with rare diseases and common conditions. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $155M | ~ 2025-04 | [ LEAD ] |